Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

Cellular and Molecular Neurobiology

Volumn 19, Issue 4, 1999, Pages 467-489

  Sánchez, Connie ^a   Hyttel, John ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

Antidepressants; Biogenic amine reuptake inhibition; In vitro; Metabolites; Receptor binding

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; CITALOPRAM; DESIPRAMINE; DOSULEPIN; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; LOFEPRAMINE; NEFAZODONE; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

DRUG ACTIVITY; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; RECEPTOR AFFINITY; REVIEW;

ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BINDING, COMPETITIVE; BIOGENIC AMINES; DEPRESSION; HUMANS; RECEPTORS, CATECHOLAMINE; RECEPTORS, SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 0032981063     PISSN: 02724340     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006986824213     Document Type: Review

References (71)

1. 1A antagonists. Trends Neurol. Sci. 19:378-383.
2. Ascher, J. A., Cole, J. O., Colin, J.-N., Feighner, J. P., Ferris, R. M., Fibiger, H. C., Golden, R. N., Martin, P., Potter, W. Z., Richelson, E., and Sulser, F. (1995). Bupropion: A review of its mechanism of antidepressant activity J. Clin. Psychiatry 56:395-401.
3. Baumann, P., and Larsen F. (1995). The pharmacokinetics of citalopram. Rev. Contemp. Pharmacother. 6:287-295.
4. Blier, P., and de Montigny, C. (1994). Current advances and trends in the treatment of depression. Trends Pharmacol. Sci. 15:220-225.
5. 1 affinity in a series of piperazine ring substituted-1-piperazino-3-arylindans with potential atypical antipsychotic activity. J. Med. Chem. 38:4380-4392.
6. 2 receptor function: Hypothesis for a faster antidepressant action. Pharmacol. Res. 30:1-11.
7. Braithwaite, R. A., Montgomery, S., and Robinson, J. D. (1978). A radioimmunoassay for amitriptyline and nortriptyline. Br. J. Pharmacol. 63:370-371.
8. Brown, A. S., and Gershon, S. (1993). Dopamine and depression. J. Neur. Transm. 91:75-109.
9. 2 receptors. Life Sci. 42:2439-2445.
10. Burch, J. E., Roberts, S. G., and Raddats, M. A. (1984). Amitriptyline and its basic metabolites determined in plasma by gas chromatography. J. Chromatogr. Biomed. Appl. 308:165-179.
11. Caccia, S., Cappi, M., Fracasso, C., and Garattini, S. (1990). Influence of dose and route of administration on the kinetics of fluoxetine and its metabolite norfluoxetine in the rat. Psychopharmacology 100:509-514.
12. Claassen, V. (1983). Review of the animal pharmacology and pharmacokinetics of fluvoxamine. Br. J. Clin. Pharmacol. 15:3498-3558.
13. de Boer, T. (1996). The pharmacologic profile of mirtazapine. J. Clin. Psychiatry 57:19-25.
14. de Bree, H., Van der Schoot, J. B., and Post, L. C. (1983). Fluvoxamine maleate disposition in man. Eur. J. Drug Metab. Pharmacokinet. 8:175-179.
15. de Paermentier, F., Cheetham, S. C., Crompton, R. M., Katona, C. L. E., and Horton, R. W. (1990). Brain β-adrenoceptor binding sites in antidepressant-free depressed suicide victims. Brain Res. 525:71-77.
16. 2 and beta-adrenergic receptors following noradrenergic or serotonergic denervation. Life Sci. 44:1419-1427.
17. Eison, A. S., Eison, M. S., Torrente, J. R., Wright, R. N., and Yocca, F. D. (1990). Nefazodone: Preclinical pharmacology of a new antidepressant. Psychopharmacol. Bull. 26:311-315.
18. Ferris, R. M., and Cooper, B. R. (1993). Mechanism of antidepressant activity of bupropion. J. Clin. Psychiatry 11:2-14.
19. Fredricson Overø, K. (1982). Kinetics of citalopram in man: Plasma levels in patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 6:311-318.
20. Fuller, R. W., Snoddy, H. D., Krushinski, J. H., and Robertson, D. W. (1992). Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 31:997-1000.
21. Goldberg, R. J. (1995). Nefazodone and venlafaxine: Two new agents for the treatment of depression. J. Family Pract. 41:591-594.
22. Goodnick, P. J. (1994). Pharmacokinetic optimization of therapy with newer antidepressants. Clin. Pharmacokin. 27:307-330.
23. Haddock, R. E., Johnson, A. M., Langley, P. F., Nelson, D. R., Pope, J. A., Thomas, D. R., and Woods, F. R. (1989). Metabolic pathway of paroxetine in animals and man and the comparative pharmacological properties of its metabolites. Acta Psychiatr. Scand. 80:24-26.
24. 1 receptors in the brain. Life Sci. 34:597-605.
25. Halper, J. P., Brown, R. P., Sweeney, J. A., Kocsis, J. H., Peters, A., and Mann, J. (1988). Blunted β-adrenergic responsivity in peripheral blood mononuclear cells in endogenous depression. Arch. Gen Psychiatry 45:241-243.
26. Heal, D., Cheetham, S., Martin, K., Browning, J., Luscombe, G., and Buckett, R. (1992). Comparative pharmacology of dothiepin, its metabolites, and other antidepressant drugs. Drug Dev. Res. 27:121-135.
27. 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 23:349-359.
28. Hrdina, P. D., Demeter, E., Vu, T. B., Sotonyi, P., and Plakovits, M. (1993). 5-HT uptake sites and 5-HT2 receptors in brain of antidepressant-free suicide victims/depressives: Increase in 5-HT2 sites in cortex and amygdala. Brain Res. 614:37-44.
29. Hyttel, J. (1982). Citalopram - Pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 6:277-295.
30. 2 receptors in corpus striatum of rats. Pharmacol. Toxicol. 61:126-129.
31. Hyttel, J. (1994). Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). J. Clin. Psychopharmacol. 9:19-26.
32. Hyttel, J., and Larsen, J.-J. (1985). Neurochemical profile of Lu 19-005, a potent inhibitor of uptake of dopamine, noradrenaline and serotonin. J. Neurochem. 44:1615-1622.
33. Hyttel, J., Overø, K. F., and Arnt, J. (1984). Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT uptake inhibitor, citalopram. Psychopharmacology 83:181-184.
34. 2 receptor antagonist. Drug Dev. Res. 15:389-404.
35. Hyttel, J., Bøgesø, K. P., Perregaard, J., and Sánchez, C. (1992). The pharmacological effects of citalopram resides in the (S)-(+)-enantiomer. J. Neur. Transm. 88:157-160.
36. Ichikawa, J., and Meltzer, H. Y. (1995). Effect of antidepressant on striatal and accumbens extracellular dopamine levels. Eur. J. Pharmacol. 281:255-261.
37. Ishida, R., Ozaki, T., Uchida, H., and Irikura, T. (1984). Gas chromatographic-mass spectrometric determination of amitriptyline and its major metabolites in human serum. J. Chromatogr. 305:73-82.
38. Iyer, R. N., and Bradberry, C. W. (1996). Serotonin-mediated increase in prefrontal cortex dopamine release: Pharmacological characterization. J. Pharmacol. Exp. Ther. 277:40-47.
39. Kaye, C. M., Haddock, R. E., Langley, P. F., Mellows, G., Tasker, T. C. G., Zussman, B. D., and Greb, W. H. (1989). A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr. Scand. 80:60-75.
40. Koe, B. K., Weissman, A., Welch, W. M, and Browne, R. G. (1983). Sertraline, 1S,4S-N-methyl-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthylamine, a new uptake inhibitor with selectivity for serotonin. J. Pharmacol. Exp. Ther. 226:686-700.
41. Lemberger, L., Bergstrom, R. F., Wolen, R. L., Farid, N. A., Enas, G. G., and Aronoff, G. R. (1985). Fluoxetine: Clinical pharmacology and physiologic disposition. J. Clin. Psychiatry 46:14-19.
42. 2 antagonists: Ritanserin and setoperone. Psychopharmacology 88:434-444.
43. Maguire, K. P., Burrows, G. D., Norman, T. R., and Scoggins, B. A. (1981). Metabolism and pharmacokinetics of dothiepin. Br. J. Clin. Pharmacol. 12:405-409.
44. 2 and beta adrenergic receptor binding in the frontal cortices of suicide victims. Arch. Gen. Psychiatry 43:954-959.
45. Martin, P., Massol, J., Colin, J. N., Lacomblez, L., and Puech, A. J. (1990). Antidepressant profile of bupropion and three metabolites in mice. Pharmacopsychiatry 23:187-194.
46. Mayol, R. F., Cole, C. A., Luke, G. M., Colson, K. L., and Kerns, E. H. (1994). Characterization of the metabolites of the antidepressant drug nefazodone in human urine and plasma. Drug Metab. Disp. 22:304-311.
47. 2 selectivity of test compounds: (1) α-adrenoceptor antagonists. Eur. J. Pharmacol. 129:49-55.
48. 3 antagonistic properties. Drug Dev. Res. 40:1-16.
49. 2C agonists exhibit antidepressant-like properties in the anhedonia model of depression in rats. Eur. Neuropsychopharmacol. 6:169-175.
50. Muth, E. A., Haskins, J. T., Moyer, J. A., Husbands, G. E. M., Nielsen, S. T., and Sigg, E. B. (1986). Antidepressant biochemical profile of the novel bicyclic compound Wy-45,030, and ethyl cyclohexanol derivative. Biochem. Pharmacol. 35:4493-4497.
51. Muth, E. A., Moyer, J. A., Haskins, J. T., Andree, T. H., and Husbands, G. E. M. (1991). Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev. Res. 23:191-199.
52. 1A receptor mediated effects of antidepressants. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 17:1-19.
53. Overmars, H., Scherpeniss, P. M., and Post, L. S. (1983). Fluvoxamine maleate: Metabolism in man. Eur. J. Drug Metab. Pharmacokin. 8:269-280.
54. 2c receptor. Psychopharmacology 126:234-240.
55. Pinder, R. M. and Wieringa, J. (1993). Third-generation antidepressants. Med. Res. Rev. 13:259-325.
56. Plym Forsyell, G. (1977). The absorption, excretion and plasma protein binding of lofepramine in the rat, dog and man. Xenobiotica 7:153-163.
57. Plym Forsyell, G., Siwers, B., and Tuck, J. R. (1976). Pharmacokinetics of lofepramine in man: relationship to inhibition of noradrenaline uptake. Eur. J. Clin. Pharmacol. 9:291-298.
58. Posner, J., Bye, A., Peck, A. W., and Whiteman, P. M. (1985). The disposition of bupropion and its metabolites in healthy male volunteers after single and multiple doses. Eur. Clin. Pharmacol. 19:97-103.
59. Schroeder, D. H. (1983). Metabolism and kinetics of bupropion. J. Clin. Psychiatry 44:79-81.
60. Schulz, P., Dick, P., Blaschke, T. F., and Hollister, L. Discrepancies between pharmacokinetic studies of amitriptyline. Clin. Pharmacokinet. 10:257-268.
61. Simon, P., Lecrubier, Y., Jouvent, R., Puech, A., and Widlocher, D. (1984). Beta-receptor stimulation in the treatment of depression. Adv. Biochem. Psychopharmacol. 39:293-299.
62. Sjögren, C. (1987). Influence of rats by antidepressants. Arzneim. Forsch. 37:1017-1020.
63. Sprouse, J., Clarke, T., Reynolds, L., Heym, J., and Rollema, H. (1996). Comparison of the effects of sertraline and its metabolite demethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 14:225-231.
64. Stern, H., Konetschny, J., Herrmann, L., Säwe, U., and Belz, G. G. (1985) Cardiovascular effects of single doses of the antidepressants amitriptyline and lofepramine in healthy subjects. Pharmacopsychiatry 78:272-277.
65. Taylor, D. P., Smith, D. W., Hyslop, D. K., Riblet, L. A., and Temple, D. L., Jr. (1986). Receptor binding and atypical antidepressant drug discovery. In O'Brien, R. A. (ed.), Receptor Binding in Drug Research, Marcel Dekker, New York.
66. Taylor, D. P., Carter, R. B., Eison, A. S., Mullins, U. L., Smith, H. L., Torrente, J. R., Wright, R. N., and Yocca, F. D. (1995). Pharmacology and neurochemistry and nefazodone, a novel antidepressant drug. J. Clin. Psychiatry 56:3-11.
67. Warrington, S. J. (1991). Clinical implications of the pharmacology of sertraline. Int. Clin. Psychopharmacol. 6:11-21.
68. Weiss, J. M., Demetrikopoulos, M. K., West, C. H. K., and Bonsall, R. W. (1996). Hypothesis linking the noradrenergic and dopaminergic systems in depression. Depression 3:225-245.
69. Welch, R. M., Lai, A. A., and Schroeder, D. H. (1987). Pharmacological significance of the species differences in bupropion metabolism. Xenobiotica 17:287-298.
70. Wong, D. T., Bymaster, F. P., Reid, L. R., Fuller, R. W., and Perry, K. W. (1985). Inhibition of serotonin uptake by optical isomers of fluoxetine. Drug Dev. Res. 6:397-403.
71. Yu, D. J., Dimmitt, D. C., Lanman, R. C., and Giesing, D. H. (1986). Pharmacokinetics of dothiepin in humans. A single dose-proportionality study. J. Pharm. Sci. 75:582-585.